WO2002078769A1 - Dispositif de collecte de composants sanguins - Google Patents
Dispositif de collecte de composants sanguins Download PDFInfo
- Publication number
- WO2002078769A1 WO2002078769A1 PCT/JP2002/002625 JP0202625W WO02078769A1 WO 2002078769 A1 WO2002078769 A1 WO 2002078769A1 JP 0202625 W JP0202625 W JP 0202625W WO 02078769 A1 WO02078769 A1 WO 02078769A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- blood component
- plasma
- container
- collection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0218—Multiple bag systems for separating or storing blood components with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
- A61M1/0231—Multiple bag systems for separating or storing blood components with gas separating means, e.g. air outlet through microporous membrane or gas bag
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/024—Means for controlling the quantity of transfused blood, e.g. by weighing the container and automatic stopping of the transfusion after reaching a determined amount
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3622—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit
- A61M1/36225—Extra-corporeal blood circuits with a cassette forming partially or totally the blood circuit with blood pumping means or components thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
Definitions
- the present invention relates to a blood component collection device that separates blood into a plurality of blood components and collects the separated blood components.
- the collected blood is separated into blood components by centrifugation, etc., and only the components necessary for the transfuser are collected. The components are collected for return to donors.
- blood collected from a donor is introduced into a blood component collection circuit, and plasma and buffer are collected by a centrifuge called a centrifugal bowl installed in the blood component collection circuit.
- a centrifuge called a centrifugal bowl installed in the blood component collection circuit.
- Platelets are separated from one coat and red blood cells, platelets are separated from the buffy coat, and collected in a container to produce a platelet product, and the remaining plasma, white blood cells and red blood cells are returned to the donor.
- this method has a problem that the probability of fever, allogeneic antigen sensitization, virus infection, and the like increases because the amount of leukocytes mixed in the platelet increases when a large number of platelets are obtained.
- the obtained platelets are passed through a leukocyte-removing filter all the time to separate and remove S blood cells, and the poorly leukocyte platelets are collected in a container to form a platelet preparation.
- An object of the present invention is to provide a blood component collecting apparatus capable of obtaining a desired high quality blood component.
- a blood component collecting apparatus made to achieve such an object has a mouth having a blood storage space therein, an inlet and an outlet communicating with the blood storage space, and the rotation of the rotor.
- a centrifugal separator for centrifuging the blood introduced from the inflow port into a plurality of blood components in the blood storage space, a first container for temporarily storing the first blood component, and a first blood component
- a blood separation device comprising: a cell separation filter that separates and removes predetermined cells from the inside; and a second container that stores the first blood component after passing through the cell separation filter.
- Flow opening and closing means for opening and closing the flow path between the cell and the cell separation filter, and control means for controlling the operation of the flow opening and closing means.
- the first blood component in the container After passing through the cell separation filter into the second container, and then supplying the second blood component, the first blood component after predetermined cells remaining in the cell separation filter have been separated and removed, It is characterized in that it is collected in the second container together with the blood component (2).
- the blood component collection device has an inlet and outlet having a blood storage space therein, an inlet and an outlet communicating with the blood storage space, and is introduced from the inlet by rotation of the rotor.
- a centrifuge for centrifuging blood into a plurality of blood components in the blood storage space, a first container for temporarily storing the first blood component, and a first container connected to the first container via a supply tube;
- a cell separation filter that separates and removes predetermined cells from the first blood component supplied through the supply tube, and a cell separation filter that is connected to the cell separation filter via a discharge tube and passed through the cell separation filter
- a second container for storing the first blood component, and a flow path opening / closing means for opening and closing the flow path of the supply tube; and a control means for controlling the operation of the flow path opening / closing means.
- the flow channel opening / closing means transfers the first blood component in the first container through the supply tube, the cell separation filter, and the discharge tube to the second container. And then supply the second blood component, which remains in the cell separation filter and in the channel of the discharge tube.
- the first blood component after separating and removing certain cells may be collected in a second container together with the second blood component.
- the blood component collection device it is desirable to adjust the total amount of blood components to be collected in the second container according to the supply amount of the second blood components. Specifically, the supply amount of the second blood component is determined based on the difference between the target total amount of the blood component to be collected in the second container and the transfer amount of the first blood component into the second container. Further, in the blood component collection device according to the present invention, the blood component collection device may include a third container for storing the second blood component, and the second blood component may be supplied from inside the third container. desirable.
- the second blood component is preferably supplied to the cell separation filter together with the first blood component remaining in the first container.
- the first blood component is plasma containing platelets
- the second blood component is plasma
- the cell separation filter is white blood cells. More preferably, it is a removal filter.
- FIG. 1 is a plan view showing the configuration of the blood component sampling device of the present invention.
- FIG. 2 is a partially cutaway cross-sectional view showing a state in which a centrifugal separator driving device is mounted on a centrifugal separator provided in the blood component collection device.
- FIG. 3 is a timing chart for explaining the operation of the blood component collecting apparatus of the present invention.
- FIG. 4 is a flowchart for explaining the operation of the blood component collecting apparatus of the present invention.
- FIG. 5 is a flowchart for explaining the operation of the blood component collecting apparatus of the present invention.
- FIG. 6 is a flowchart for explaining the operation of the blood component collecting apparatus of the present invention.
- FIG. 7 is a flow chart for explaining the operation of the blood component collecting apparatus of the present invention. It is.
- FIG. 8 is a flowchart for explaining the operation of line cleaning in the blood component sampling apparatus of the present invention.
- FIG. 1 is a plan view showing a configuration of a blood component collection device of the present invention
- FIG. 2 is a partially broken cross-section in a state where a centrifuge drive device is mounted on a centrifuge provided in the blood component collection device.
- FIG. 3 is a timing chart for explaining the operation of the blood component sampling device of the present invention.
- 4 to 7 are flow charts for explaining the operation of the blood component collecting apparatus of the present invention, respectively.
- FIG. 8 is an operation of the line cleaning operation in the blood component collecting apparatus of the present invention. This is a flowchart for explaining the operation.
- the blood component collection device 1 shown in FIG. 1 is a device for separating blood into a plurality of blood components and collecting the separated blood components (particularly, platelets). , which has an inlet 1 4 3 and an outlet 1 4 4 communicating with the blood storage space 1 4 6, and was introduced from the inlet 1 4 3 by the rotation of the rotor 1 4 2
- the second line 22 connected to the outlet 14 of the second 20, the third line 23 connected to the first line 21, and the second line 22 connected to the first line 21.
- the blood component collection device 1 includes a centrifuge drive device 10 for rotating the rotor 144 of the centrifuge 20 and a first liquid transfer for the first line 21.
- a control unit (control means) 13 for controlling the 8 87, a turbidity sensor 14, an optical sensor 15, and a weight sensor 16.
- This blood component collection circuit 2 connects a blood collection needle (blood collection means) 29 for collecting blood and an inlet 144 of a centrifuge 20 and includes a first pump tube 21 g Line (blood collection and return line) 2 1, 2nd line 2 2 for connecting outlet 1 4 4 of centrifuge 20 with 1st line 21, 1st line 2 1 Of the third line (anticoagulant injection line) 23, which is connected near the blood collection needle 29, and has the second pump tube 23a, and the pump line 21g of the first line 21
- a plasma collection bag 25 having a first tube 25 a connected to the blood collection needle 29 side and a second tube 25 b connected to the second line 22, and a second line 22.
- Platelet collection bag 26 with connected third tube 26a and puffy sample collection with fourth tube 27a connected to second line 22 Bag 27 is provided.
- the blood collection means is not limited to the blood collection needle 29, but may be, for example, a connection portion (for example, a metal or synthetic resin needle) for connecting to a blood pool such as a blood bag.
- a connection portion for example, a metal or synthetic resin needle
- the blood collection needle 29 for example, a known metal needle is used.
- the first line 21 is a first line 21 a connected to the blood collection needle to which the blood collection needle 29 is connected, and a first line 21 connected to the inlet 14 of the centrifuge 20. 2 1 b.
- the first line 21a on the blood collection needle side is formed by connecting a plurality of soft resin tubes.
- the blood collection needle side first line 21 a is connected from the blood collection needle 29 side to a branch connector 21 c for connection to the third line 23, and a chamber 1 2 I for removing bubbles and microaggregates.
- Branch connector for connection between d and the second line 22
- One 21 e and a branch connector 21 f for connection with the first tube 25 a of the plasma collection bag 25.
- a gas-permeable and bacteria-impermeable filter 21 i is connected to the chamber 21 d.
- 2 lb of the first line on the centrifugal separator side is connected to the branch connector 1 1f for connection to the first tube 25a, and the first pump tube 21 formed near it. has g.
- the second line 22 connecting the outlet 144 of the centrifuge 20 to the first line 21 has one end connected to the outlet 144 of the centrifuge 20 and the other end. Are connected to the connection branch connector 1 2 e of the first line 21.
- This second line 22 is connected from the centrifuge 20 side to a branch connector for connection with the second tube 25 b of the plasma collection bag 25 and the third tube 26 a of the platelet collection bag 26.
- One end of the third line 23 is connected to a connection branch connector 21 c provided on the first line 21.
- the third line 23 is connected from the connector 21c side to a second pump tube 23a, a foreign matter removing filter 23b, a bubble removing chamber 23c, and an anticoagulant. And a drug container connecting needle 23d.
- the plasma collection bag (third container) 25 is a container for collecting (retaining) plasma (second blood component), and a blood collection needle is taken from the pump tube 21 g of the first line 21
- the first tube 25a is connected to the branch connector 21f located on the side of the second line 29, and the second tube 25b is connected to the branch connector 22a of the second line 22. I have. That is, the plasma collection bag 25 and the second tube 25 b constitute a plasma collection branch line for collecting plasma.
- the platelet collection bag (second container) 26 is a container for collecting (reserving) platelet-containing plasma (first blood component) after passing through a leukocyte removal filter 261, which will be described later.
- 2 line 2 2 branch connector 1 2 a It has three tubes 26a.
- the platelet-containing plasma (first blood component) is referred to as “rich platelet plasma”
- the concentrated platelet plasma collected (stored) in the platelet collection bag 26 is referred to as “platelet preparation”.
- a temporary storage bag (first container) 26 ′ for temporarily storing the concentrated platelet plasma (the first blood component) and the concentrated platelet plasma
- a leukocyte removal filter (cell separation filter) is installed to separate and remove leukocytes (predetermined cells) from the cell.
- the third tube 26a is composed of three tubes 261a, 262a and 263a, and the tube 261a is connected to the branch connector 22a.
- the tube 26 2 a connects the temporary storage bag 26 5 and the leukocyte depletion filter 21, and the tube 26 3 a is the leukocyte depletion filter.
- 26 1 and platelet (platelet product) collection bag 26 are connected.
- Tube 2 6 2 a constitutes a supply tube for supplying temporary dark thick platelet plasma from the reservoir bag 2 6 5 leukocyte removal fill evening one
- the tube 2 6 3 a is a leukocyte removal filter 2 6 1 Drain the concentrated platelet plasma after separating and removing leukocytes (supply to platelet collection bag 26) Configure drain tube. That is, the third tube 26a (tube 26 la, 26 2a, 26 3a), the temporary storage bag 26 ', the leukocyte removal filter 26 1 and the platelet collection bag 26 A branch line for collecting platelets for collecting) is configured.
- the temporary storage bag 26 ′, the leukocyte removal filter 26 1, and the platelet collection bag 26 are assembled with the blood component collection device 1, and the leukocyte removal filter 26 1 is attached to the temporary storage bag 26, At a lower position, the platelet collection bag 26 is set at a position lower than the leukocyte removal filter 261.
- the leukocyte removal filter 261 for example, in a casing having an inlet and an outlet at both ends, for example, a woven fabric, a nonwoven fabric, a mesh made of a synthetic resin such as polypropylene, polyester, polyurethane, polyamide, etc. It is also constructed by inserting a filter member in which one or more layers of a porous material such as a foam are laminated. Can be used.
- the buffy coat collection bag 27 is a container for collecting a buffy coat, and includes a fourth tube 27 a connected to the branch connector 22 d of the second line 22. That is, the buffy coat collecting bagg 27 and the fourth tube 27a constitute a buffy coat collecting branch line for collecting the buffy coat.
- each tube used to form the first to third lines 21-23 described above, each pump tube 21g, 23a, and each tube 25a, 25 connected to each bag 25-27 As a constituent material of b, 26a (261a, 262a, 263a) and 27a, polyvinyl chloride is preferable.
- these tubes are made of polyvinyl chloride, sufficient flexibility and flexibility can be obtained, so that they are easy to handle and are also suitable for clogging with clamps or the like.
- the pump tubes 21g and 23a each have a strength such that they are not damaged even if they are pressed by the liquid feeding pumps (for example, roller-to-pump etc.) 11 and 12 described later. Have been.
- the plasma collection bag 25, the platelet collection bag 26, the temporary storage bag 26, and the buffer coat collection bag 27 each overlap a resin-made flexible sheet material and fuse the peripheral edge thereof (heat fusion). , High-frequency welding, ultrasonic welding, etc.) or a bag made by bonding with an adhesive is used.
- the sheet material used for the platelet collection bag 26 it is more preferable to use a sheet material having excellent gas permeability in order to improve platelet preservability.
- a sheet material for example, polyolefin or DnDP plasticized polyvinyl chloride is used. It is preferable to use a sheet material made of such a material and make the thickness relatively thin (for example, about 0.1 to 0.5 mm, particularly about 0.1 to 0.3 mm).
- a platelet preservation solution such as GAC, PAS, or PSM-1 may be previously stored in the platelet collection bag 26, for example.
- the main part of the blood component sampling circuit 2 is a cassette type as shown in FIG. That is, the blood component collection circuit 2 includes each line (first line 21, second line 22, third line 23) and each tube (first tube 25 a, second tube 25b, 3rd tube 26a, 4th tube 27a) are partially housed and partially held, in other words, the cassette housing in which they are partially fixed It has 2 8.
- Both ends of the first pump tube 2lg and both ends of the second pump tube 23a are fixed to the force set housing 28, and these pump tubes 21g and 23a are respectively From the cassette housing 28, each liquid feed pump (for example, a roller pump, etc.) protrudes in a loop shape corresponding to the shapes of 11 and 12. For this reason, the first and second pump tubes 21g and 23a can be easily mounted on the respective liquid transfer pumps 11 and 12 respectively.
- each liquid feed pump for example, a roller pump, etc.
- the cassette housing 28 has a plurality of openings 91 to 96 located in the cassette housing 28.
- the centrifuge 20 provided in the blood component collecting circuit 2 is usually called a centrifuge bowl, and separates blood into a plurality of blood components by centrifugal force.
- the centrifugal separator 20 has a vertically extending pipe 14 1 having an inlet 14 3 formed at the upper end, and a pipe 14 1 rotating around the pipe 14 1. It has a hollow mouth that is sealed liquid-tight with respect to 45.
- An annular blood storage space 146 is formed in the rotor 144 along the inner surface of the peripheral wall.
- This blood storage space 146 has a shape (taper shape) whose inner and outer diameters gradually decrease from the lower part to the upper part in FIG. 2, and the lower part extends along the bottom of the rotor 144. Through the substantially disk-shaped flow path formed in this way, it communicates with the lower end opening of the tubular body 141, and the upper part thereof communicates with the discharge port 144.
- the volume of the blood storage space 1 46 is, for example, about 100 to 35 O mL
- the maximum inner diameter (maximum radius) from the rotation axis of the mouth of the mouth 142 is, for example, about 55 to 65 mm.
- Such a mouth 142 rotates under predetermined centrifugation conditions (rotational speed and rotation time) preset by the centrifuge driving device 10 provided in the blood component collection device 1.
- a blood separation pattern for example, the number of blood components to be separated
- FIG. 2 the blood layer 13 1, the buffy coat layer 13 2 and the red blood cell layer 1 33. Centrifugation conditions are set so that separation is performed.
- the blood component collection device 1 includes a centrifugal separator driving device 10 for rotating the mouth of the centrifuge 20, and a first feeding device installed in the middle of the first line 21.
- the blood component collection device 1 is connected to the second tube 25 b from the connection portion 22 a, and the turbidity sensor attached (installed) to the second line 22 on the centrifuge 20 side (upstream side).
- the control unit 13 includes two pump controllers (not shown) for the first liquid supply pump 11 and the second liquid supply pump 12, and the control unit 13 and the first liquid supply pump
- the first and second liquid sending pumps 12 are electrically connected via a pump controller.
- the drive controller (not shown) of the centrifuge drive device 10 includes a control unit It is electrically connected to 13.
- Each of the flow passage opening / closing means 81 to 87 is electrically connected to the control unit 13.
- the turbidity sensor 14, the optical sensor 15 and the weight sensor 16 are electrically connected to the control unit 13 respectively.
- the control unit 13 is formed of, for example, a micro-combiner.
- the control unit 13 receives detection signals from the turbidity sensor 14, the optical sensor 15 and the weight sensor 16 described above. , Is entered at any time.
- control unit 13 Based on the detection signals from the turbidity sensor 14, the optical sensor 15, and the weight sensor 16, the control unit 13 operates the components of the blood component collection device 1 according to a preset program, that is, Controls the rotation, stop, and rotation direction (forward / reverse) of each liquid feed pump 11, 12 and, if necessary, opens and closes each channel opening / closing means 8 1 to 87 and drives the centrifuge. Controls the operation of 10.
- the first channel opening / closing means 81 is provided for opening / closing the first line 21 on the blood collection needle 29 side from the first pump tube 21 g.
- the second channel opening / closing means 82 is provided for opening and closing the first tube 25 a of the plasma collection bag 25.
- the third channel opening / closing means 83 is provided for opening and closing the second tube 25 b of the plasma collection bag 25.
- the fourth channel opening / closing means 84 is provided for opening / closing the third tube 26 a (tube 26 1 a) of the platelet collection bag 26.
- the fifth flow path opening / closing means 85 is located on the centrifugal separator 20 side from the connection portion (branch connector 2 2 d) between the second line 22 and the fourth tube 27 a of the buffy coat collection bag 27. It is provided at the (upstream) position to open and close the second line 22.
- the sixth flow path opening / closing means 86 is provided between a connection portion (branch connector 21e) of the first line 21 and a connection portion (branch connector 22d) of the fourth tube 27a (branch connector 22d). At a position (downstream from the connection between the second line 22 and the fourth tube 27a), the second line 22 is provided for opening and closing.
- the seventh channel opening / closing means 87 is provided to open / close the third tube 26a (tube 26a).
- Each of the flow passage opening / closing means 8 1 to 8 7 includes a first line 21, a second line 22, a first tube 25 a, a second tube 25 b, and a third tube 26 a (
- the tube 26 1 a, 26 2 a) is provided with an insertion portion into which the clamp can be operated by a drive source such as a solenoid, an electric motor, or a cylinder (hydraulic or pneumatic).
- a drive source such as a solenoid, an electric motor, or a cylinder (hydraulic or pneumatic).
- a solenoid such as a solenoid, an electric motor, or a cylinder (hydraulic or pneumatic).
- an electromagnetic clamp operated by a solenoid is preferable.
- the centrifugal separator driving device 10 includes a housing 201 for accommodating the centrifugal separator 20, a leg portion 202, and a motor source 203 as a driving source. And a disk-shaped fixed base 205 that holds the centrifugal separator 20.
- the housing 201 is placed and fixed on the upper part of the leg portion 202.
- a motor 203 is fixed to a lower surface of the housing 201 by a bolt 206 via a spacer 206.
- a fixed base 205 is fitted so as to rotate coaxially and integrally with the rotating shaft 204.
- a recess is formed in which the bottom of the mouth is fitted.
- the upper part 144 of the centrifuge 20 is fixed to the housing 201 by a fixing member (not shown).
- An optical sensor 15 is installed on the side of the housing 201 (the left side in FIG. 2).
- the optical sensor 15 is configured to project light toward the blood storage space 144 and receive the reflected light.
- the optical sensor 15 emits light (for example, laser light) from the light emitting section 15 Then, the light reflected by the reflective surface 14 7 of the mouth 14 1 is received by the light receiving section 15 2. The light is then converted by the light receiving section 152 into an electric signal corresponding to the amount of received light.
- light for example, laser light
- the projected light and the reflected light respectively transmit the blood components in the blood storage space 146, but at the interface of the blood components (in this embodiment, the plasma layer 13 1 and the buffy coat).
- the ratio of each blood component at the position where the projected light and the reflected light are transmitted differs, so that their transmittance changes.
- the amount of light received by the light receiving section 152 fluctuates (changes), and this fluctuation can be detected as a change in the output voltage from the light receiving section 152.
- the optical sensor 15 can detect the position of the interface of the blood component based on the change in the amount of light received by the light receiving unit 152.
- the interface of the blood component detected by the optical sensor 15 is not limited to the interface B, and may be, for example, an interface between the buffer layer 1332 and the red blood cell layer 133.
- each layer 1 3 1 to 1 3 3 in the blood storage space 1 4 6 has a different liquid color depending on the blood component.
- the red blood cell layer 1 3 3 has a red color according to the color of the red blood cells. It has a color.
- this wavelength range is not particularly limited. For example, 600 to 900 nm It is preferably about 750 to 800 nm, more preferably about 750 to 800 nm.
- the turbidity sensor 14 is for detecting the turbidity of the fluid flowing in the second line 22 and outputs a voltage value corresponding to the turbidity. Specifically, a low voltage value is output when turbidity is high, and a high voltage value is output when turbidity is low.
- the turbidity sensor 14 can detect, for example, replacement of the fluid flowing in the second line 22 with air from the air, change in the concentration of platelets in the plasma, and contamination of the blood cells with the red blood cells. it can.
- the first liquid transfer pump 11 to which the first pump tube 21g is attached and the second liquid transfer pump 12 to which the second pump tube 23a is attached are as follows.
- a non-blood contact type pump such as a roller pump is preferably used. You.
- FIG. 3 is a timing chart showing the outline of the first cycle in the blood component collecting operation using the blood component collecting apparatus 1.
- the blood component collection device 1 controls the first plasma collection process (A), the constant speed plasma circulation process (B), and the second plasma collection process under the control of the control unit 13.
- the platelet collection operation includes (C), an accelerated plasma circulation step (D), a third plasma collection step (E), a platelet collection step (F), and a blood return step. Further, in the present embodiment, the platelet collection operation is repeated three times (first cycle to third cycle), and after the platelet collection process (F) other than the final one (third cycle), The buffy coat collection step (G) should be performed before the blood return step, and the puffy coat return step should be performed before the start of the first plasma collection step (A) in the next platelet collection operation. Has become.
- the blood component collection apparatus 1 in parallel to perform platelet collection operation the last cycle, the blood component collection apparatus 1, under the control of the control unit 1 3, temporarily collected (stored) in the temporary reservoir bag 2 6 5
- the obtained concentrated platelet plasma is supplied to a leukocyte removal filter 261, and a filtration operation for separating and removing leukocytes in the concentrated platelet plasma is performed (see S401 in FIG. 8).
- a filtration operation for separating and removing leukocytes in the concentrated platelet plasma is performed (see S401 in FIG. 8).
- the blood component collection device 1 of the present embodiment is configured to start the filtration operation almost simultaneously with the start of the second plasma collection step (C) in the platelet collection operation in the final cycle.
- the third line 23 and the blood collection needle 29 were brassed with an anticoagulant. After that, the blood sampling needle 29 is punctured into the blood vessel of the donor (blood donor).
- the blood component collection device 1 performs the first plasma collection (first PPP collection) step (A).
- first plasma collection process (A) blood is introduced into the blood storage space 146 of the mouth 142, and the plasma (PPP) separated by centrifuging the blood is collected in the plasma collection bag 25. .
- the control section 13 collects plasma (second blood component) (step S101 in FIG. 4).
- the first channel opening / closing means 81 and the fourth channel opening / closing means 84 are opened, and the first channel
- the liquid pump 11 is operated (forward rotation) at a predetermined rotation speed (preferably, about 25 OmLZmin or less, more preferably, about 40 to 150 mLZmin, and in this embodiment, 6 OmL / min). Start blood collection from.
- the second liquid feed pump 12 is operated under the control of the control unit 13 to supply an anticoagulant such as ACD-A solution via the third line 23. Then, this anticoagulant is mixed into the collected blood.
- the rotation speed of the second liquid feeding pump 12 is controlled by the control unit 13 at a predetermined ratio (preferably about 1/20 to 1/6, for example, 1/10) of the anticoagulant to the blood collection blood. Controlled to be mixed.
- blood blood with anticoagulant
- the first line 21 blood (blood with anticoagulant) is transferred through the first line 21 and introduced into the blood storage space 146 of the rotor 142 via the tube 141 from the inlet 143 of the centrifuge 20. Is done.
- the air (sterilized air) in the centrifuge 20 is sent into the temporary storage bag 26, via the second line 22 and the third tube 26a.
- control unit 13 activates the centrifuge driving device 10 to control the rotor 142 to rotate at a predetermined rotation speed.
- the blood introduced into the blood storage space 146 is converted from the inside into the plasma layer (PPP layer) 131, buffy coat layer (BC layer) 132, red Blood cell layer (CRC layer) 133 layers are separated.
- PPP layer plasma layer
- BC layer buffy coat layer
- CRC layer red Blood cell layer
- the rotation speed of the mouth 142 is preferably about 3000 to 6000 rpm, more preferably about 4200 to 5800 rpm. Further, in the following steps, the control unit 13 does not change the number of rotations of the opening and closing process 142 unless otherwise specified.
- the turbidity sensor 14 installed in the second line 22 detects that the fluid flowing in the second line 22 has changed from air to plasma, and the control unit 13 sends the turbidity sensor 14 Based on this detection signal, control is performed such that the fourth flow path opening / closing means 84 is closed and the third flow path opening / closing means 83 is opened.
- the plasma is introduced into the plasma collection bag (third container) 25 via the second line 22 and the second tube 25 b. And collected.
- the weight of the plasma collection bag 25 is measured by the weight sensor 16, and the measured weight signal is input to the control unit 13.
- control unit 13 determines whether or not a predetermined amount of plasma has been collected in the plasma collection bag 25 based on the information (weight signal) from the weight sensor 16 (Step S102 in FIG. 4).
- the amount (predetermined amount) of the collected plasma is preferably about 10 to 150 g, more preferably about 20 to 40 g.
- step S102 If a predetermined amount of plasma has not been collected in the plasma collection bag 25 in step S102, the control unit 13 returns to step S101, and repeats step S101 and subsequent steps again.
- step S102 If a predetermined amount of plasma has been collected in the plasma collection bag 25 in step S102, the control unit 13 terminates this step [11] (first plasma collection step (A)). Then, proceed to the constant-speed plasma circulation process (B).
- the blood component collection device 1 performs a constant-speed plasma circulation (constant-speed PPP circulation). Perform step (B).
- the plasma in the plasma collection bag 25 is circulated in the blood storage space 146 at a constant speed.
- the controller 13 circulates plasma (step S103 in FIG. 4).
- the first flow path opening / closing means 81 is closed, the second flow path opening / closing means 82 is opened, and the second liquid supply pump 12 is stopped.
- the blood collection is temporarily stopped, and the plasma in the plasma collection bag 25 is introduced at a constant speed into the blood storage space 146 through the first tube 25a and the first line 21, and the outlet of the centrifugal separator 20 is discharged.
- the plasma flowing out of 144 is collected in the plasma collection bag 25 via the second line 22 and the second tube 25b. That is, the plasma in the plasma collection bag 25 is circulated in the blood storage space 146 at a constant speed.
- the control unit 13 determines whether a predetermined time (preferably about 10 to 90 seconds, for example, 30 seconds) has elapsed since the start of the constant-speed PPP circulation (step S104 in FIG. 4). .
- step S104 If it is determined in step S104 that the predetermined time has not elapsed since the start of the constant-speed PPP circulation, the control unit 13 returns to step S103 and repeats step S103 and subsequent steps again.
- step S104 if a predetermined time has elapsed since the start of the constant-speed PPP circulation, the control unit 13 terminates this step [12] (the constant-speed plasma circulation step (B)), Move to the second plasma collection step (C).
- the blood component sampling apparatus 1 performs the second plasma sampling (second PPP sampling) step (C).
- second plasma collection step (C) blood is introduced into the blood storage space 146 of the rotor 142, and the blood separated by centrifugation of the blood is collected in the plasma collection bag 25.
- the interface between the plasma layer 131 and the buffy coat layer 132 was used. Except for detecting the position of B, the same steps as in the above step [11] (first plasma collection step (A)) are performed.
- the control unit 13 collects plasma (step S105 in FIG. 4).
- control unit 13 controls to close the second flow path opening / closing means 82 and open the first flow path opening / closing means 81.
- the interface B also gradually rises (moves in the direction of the rotation axis of the mouth 142).
- control unit 13 determines whether or not the interface B has reached a predetermined level (first position) based on a detection signal (interface position detection information) from the optical sensor 15 (FIG. 4). Step S 106).
- the first position of the interface B is a position at which the detection signal (output voltage from the light receiving unit 152) from the first optical sensor 15 becomes preferably about 1 to 2 V. You.
- step S106 If the interface B has not reached the first position in step S106, the control unit 13 returns to step S105, and repeats step S105 and subsequent steps.
- step S105 If the interface: B has reached the first position in step S105, the control unit 13 terminates this step [13] (second plasma collection step (C)) and returns Move to plasma circulation step (D).
- the blood component sampling device 1 performs the accelerated plasma circulation (accelerated PPP circulation) process (D).
- the plasma in the plasma collection bag 25 is circulated while accelerating into the blood storage space 146.
- the control section 13 circulates the plasma (step S107 in FIG. 4).
- the first flow path opening / closing means 81 is closed, the second flow path opening / closing means 82 is opened, and the second liquid supply pump 12 is stopped, and The rotation speed of the first liquid transfer pump 11 increases (increases) at a constant acceleration. (Forward rotation).
- the blood collection is temporarily interrupted, and the plasma in the plasma collection bag 25 is introduced into the blood storage space 146 while being accelerated through the first tube 25a and the first line 21, and the outlet of the centrifuge 20 is discharged.
- the plasma flowing out of 144 is collected into the plasma collection bag 25 via the second line 22 and the second tube 25b. That is, the plasma in the plasma collection bag 25 is circulated while accelerating into the blood storage space 146.
- control unit 13 changes the rotation speed of the first liquid feed pump 11 from a speed lower than the constant speed PPP circulation (initial speed: 6 OmL / min in the present embodiment) at a constant acceleration. Control to increase (increase).
- the acceleration condition is preferably about 1 to 10 mL / min / sec, more preferably about 3 to 6 mL / min / sec.
- the acceleration is fixed, but may be changed stepwise or continuously within the above range.
- control unit 13 determines whether the circulation speed of the plasma into the blood storage space 146 has reached the maximum speed, that is, whether the rotation speed of the first liquid supply pump 11 is the maximum speed (preferably 130 to 250 It is determined whether the flow rate has reached about mL / min (17 OmL / min in the present embodiment) (step S108 in FIG. 4).
- This step S108 is continued until the circulation speed of the plasma into the blood storage space 146 reaches the maximum speed.
- step S108 when the circulation speed of the plasma into the blood storage space 146 reaches the maximum speed, the control unit 13 ends the present process [14] (the accelerated plasma circulation process (D)), and Proceed to step 3 (E) for plasma collection.
- the blood component sampling device 1 performs the third plasma sampling (third PPP sampling) step (E).
- third plasma collection step (E) blood is introduced into the blood storage space 146 of the rotor 142, and the plasma separated by centrifuging the blood is collected in the plasma collection knob 25.
- the control unit 13 collects plasma (step S109 in FIG. 4). Next, the control unit 13 determines whether or not a predetermined amount of plasma has been collected in the plasma collection bag 25 based on information (weight signal) from the weight sensor 16 (step S 1 in FIG. 4). Ten ) .
- the collection amount (predetermined amount) of the plasma is preferably about 2 to 30 g, and more preferably about 5 to 15 g.
- step S110 If a predetermined amount of plasma has been collected in the plasma collection bag 25 in step S110, the control unit 13 executes this step [15] (third plasma collection step (E)). ) Is completed, and the process proceeds to the platelet collection process (F) (the process proceeds to (1) in Fig. 5).
- the blood component collection device 1 performs a platelet collection (PC collection) step (F).
- the plasma in the plasma collection bag 25 is circulated in the blood storage space 146 while accelerating at the first acceleration, and then the second acceleration larger than the first acceleration is performed. And then circulates while accelerating at this second acceleration, allowing platelets to flow out of the blood storage space 146, and collecting concentrated platelet plasma in the temporary storage bag 26 '. I do.
- the control unit 13 performs plasma circulation (PPP circulation) with the first acceleration (first acceleration step in FIG. 3, step S111 in FIG. 5). Specifically, under the control of the control unit 13, the first flow path opening / closing means 81 is closed, the second flow path opening / closing means 82 is opened, and the second liquid feed pump 12 is stopped. And operates (forward rotation) to increase (increase) the rotation speed of the first liquid sending pump 11 at the first acceleration.
- the blood collection is interrupted, and the plasma in the plasma collection bag 25 is accelerated into the blood storage space 1466 at the first acceleration rate via the first tube 25a and the first line 21.
- the plasma in the plasma collection bag 25 is circulated in the blood storage space 146 while being accelerated at the first acceleration.
- the first acceleration is preferably about 0.5 to 10 mL / min / sec, more preferably about 1.5 to 2.5 mL / min / sec. Although the first acceleration is constant in the present embodiment, it may be changed stepwise or continuously within the above range.
- the initial speed of the first liquid feed pump 11 in the PPP circulation at the first acceleration is preferably about 40 to 15 OmL / min, more preferably about 50 to 8 OmL / min. In the present embodiment, the initial speed of the first liquid sending pump 11 is set to 60 mL / min.
- the control unit 13 continues step S111 until the circulation speed of the plasma into the blood storage space 146 reaches a predetermined speed (step S112 in FIG. 5).
- the circulation rate of the plasma that is, the rotation speed of the first liquid supply pump 11 is preferably about 100 to 180 mL / min, and more preferably about 140 to 16 OmL / min. You. In the present embodiment, the rotation speed of the first liquid sending pump 11 is set to 150 mL / min.
- the control unit 13 performs the plasma circulation (PPP circulation) with the second acceleration (third acceleration).
- the acceleration of the first liquid transfer pump 11 is changed from the first acceleration to the second acceleration, and the rotation speed of the first liquid transfer pump 11 is changed. Operates (forward rotation) to increase (increase) at the second acceleration.
- the plasma in the plasma collection bag 25 is circulated in the blood storage space 146 while being accelerated at the second acceleration.
- the thickness of the red blood cell layer 133 increases, and the interface B also gradually increases (in the direction of the rotation axis of the rotator 142).
- the platelets (PC) in the buffy coat layer 132 rise (float) against the centrifugal force and move toward the outlet 144 of the rotor 142.
- the second acceleration is set to be larger than the first acceleration, preferably about 3 to 20 mL / min / sec, and more preferably 5 to 10 mL / min. sec. Although the second acceleration is constant in the present embodiment, the second acceleration may be changed stepwise or continuously within the above range.
- control unit 13 determines whether or not the circulation speed of the plasma into the blood storage space 146 has reached the maximum speed, that is, the rotation speed of the first liquid feed pump 11 is the maximum speed (preferably 120 to 300 mL). / min (in this embodiment, 200 mL / min) (step S114 in FIG. 5).
- step S114 If it is determined in step S114 that the circulation speed of the plasma into the blood storage space 146 has not reached the maximum speed, the control unit 13 returns to step S113 and repeats step S113 and subsequent steps.
- step S114 when the circulation speed of the plasma into the blood storage space 146 reaches the maximum speed, the control unit 13 performs the plasma circulation continuation (PPP circulation continuation) (step S115 in FIG. 5). ).
- the control unit 13 controls the rotation speed of the first liquid feed pump 11 to be maintained (held) at the maximum speed in step S115.
- the circulation rate of the plasma into the blood storage space 146 is preferably set to about 120 to 300 mL / min. In the present embodiment, it is set to 20 OmL / min.
- control unit 13 determines whether or not a predetermined time (preferably about 5 to 15 seconds, for example, 10 seconds) has elapsed since the start of the continuation of the PPP circulation (step S116 in FIG. 5).
- a predetermined time preferably about 5 to 15 seconds, for example, 10 seconds
- step S116 if the predetermined time has not elapsed since the start of the PPP circulation continuation, the control unit 13 then sets the output voltage (PC concentration voltage) from the turbidity sensor 14 to a predetermined value (preferably, It is determined whether the voltage has dropped to about 2.5 to 3.5 V (for example, 3.0 V) (step S117 in FIG. 5).
- a predetermined value preferably, It is determined whether the voltage has dropped to about 2.5 to 3.5 V (for example, 3.0 V)
- step S117 If the output voltage from the turbidity sensor 14 has not fallen below the predetermined value in step S117, the control unit 13 returns to step S115 and repeats step S115 and subsequent steps again.
- Step S116 While repeating Steps S115 to S117, in Step S116, if a predetermined time has elapsed since the start of the continuation of the PPP circulation, the control unit 13 executes this process [16] (Platelet collection process (F)) Move to sampling process (G).
- control unit 13 collects platelets (PC) (step S118 in FIG. 5).
- control unit 13 controls the third channel opening / closing unit 83 to be closed and the fourth channel opening / closing unit 84 to be opened based on the detection signal of the turbidity sensor 14.
- control unit 13 calculates the platelet concentration (cumulative PC concentration) in the temporary storage bag 26, based on the output voltage (detection signal) from the turbidity sensor 14. The platelet concentration continues to increase after the start of PC collection, and once it reaches the maximum concentration, it starts to decrease.
- control unit 13 determines whether or not a predetermined time (preferably about 10 to 25 seconds, for example, 15 seconds) has elapsed since the start of the PC collection (step S119 in FIG. 5). .
- a predetermined time preferably about 10 to 25 seconds, for example, 15 seconds
- step S119 if the predetermined time has not elapsed since the start of the PC sampling, then the control unit 13 determines that the output voltage (PC concentration voltage) of the turbidity sensor 14 has reached the predetermined value or less. It is determined whether or not (step S120 in FIG. 5).
- the predetermined value of the output voltage of the turbidity sensor 14 is a value near the time when red blood cells (CRC) are mixed into the plasma flowing through the second line 22, and is preferably about 0.5 V or less. Is done.
- step S120 if the output voltage of the turbidity sensor 14 has not reached the predetermined value or less, the control unit 13 then controls the concentrated platelet plasma in the temporary storage bag 26 'to reach the predetermined amount.
- the amount (predetermined amount) of the concentrated platelet plasma is preferably about 20 to 10 OmL, more preferably about 40 to 7 OmL.
- Step S 1 2 when the platelet concentrate in the temporary reservoir bag 26 5 does not reach to a predetermined quantitative, the control unit 13 returns to step S 1 18, and repeats the subsequent steps S 1 1 8.
- step S119 if a predetermined time has elapsed since the start of the PC sampling, or in step S120, the turbidity sensor 14
- step S120 if a predetermined time has elapsed since the start of the PC sampling, or in step S120, the turbidity sensor 14
- the control unit 13 ends the present step [16] (platelet collection step (F)) and shifts to the buffy one coat collection step (G).
- step S121 when the concentrated platelet plasma in the temporary storage bag 26 'reaches a predetermined amount, the control unit 13 terminates this step [16] (the platelet collection step (F)). Then, it shifts to the buffy coat collection process (G).
- the blood component collection device 1 performs a buffy coat collection (BC collection) process (G).
- BC collection buffy coat collection
- the buffy coat is discharged from the blood storage space 146 of the mouth 142 and collected.
- the control unit 13 collects a buffy coat (step S122 in FIG. 5).
- the fourth flow path opening / closing means 84 is closed, the fifth flow path closing means 85 is opened, and the first liquid feed pump 11 is rotated by a predetermined rotation. It operates (forward rotation) at a speed (preferably about 60 to 30 OmL / min, in this embodiment, 200 mL / min).
- the plasma in the plasma collection bag 25 is introduced at a predetermined speed into the blood storage space 146 through the first tube 25a and the first line 21 and the buffy coat that has flowed out from the outlet 144 of the rotor 142. Is introduced into the buffy coat collection bag 27 via the second line 22 and the fourth tube 27a and collected.
- the control unit 13 changes the rotation speed of the mouth 142.
- the rotation speed of the rotor 142 is determined in the above steps [11] to [16].
- the rotation speed is set to be lower by about 100 to 300 rpm than the rotation speed of the rotor, and specifically, it is preferably about 450 to 460 rpm.
- control unit 13 determines whether or not a predetermined amount of buffy coat has been collected in the buffy coat collection bag 27 (step S 1 23 in FIG. 5).
- control unit 13 calculates the collection amount (predetermined amount) of the buffy coat from the blood collection amount, the hematocrit value of the donor, and the amount of platelets collected in the platelet collection step.
- the number of rotations of the first liquid supply pump 11 is determined from the amount, and it is determined whether the first liquid supply pump 11 has rotated the number of times necessary to collect the calculated collection amount.
- step S123 if a predetermined amount of buffy coat has not been collected in the buffy coat collection bag 27, that is, if the first liquid feed pump 11 has not been rotated the required number of times. To this end, the control unit 13 returns to step S122 and repeats step S122 and subsequent steps again.
- the blood component collection device 1 performs a step of stopping the centrifugal separator 20.
- control unit 13 decelerates the centrifugal separator 20 (Step S124 in FIG. 5).
- the rotation speed of the centrifugal separator drive device 10 is reduced, and the rotor 142 is decelerated.
- control unit 13 stops the centrifuge 20 (step S125 in FIG. 5).
- the rotation of the centrifugal separator drive device 10 is stopped, and the mouth unit 142 is stopped.
- the blood component collection device 1 performs a blood return step.
- the blood components in the blood storage space 146 of the rotor 142 are returned.
- the control unit 13 returns blood (step S126 in FIG. 5). Specifically, under the control of the control unit 13, the first flow path opening / closing means 81 is opened, and the first liquid sending pump 11 is rotated at a predetermined rotation speed (preferably about 20 to 120 mL / min). Operate (reverse) at, for example, 9 OmL min).
- a predetermined rotation speed preferably about 20 to 120 mL / min. Operate (reverse) at, for example, 9 OmL min).
- the blood components mainly red blood cells
- the blood components remaining in the blood storage space 146 of the low blood pressure 142 are discharged from the outlet 144 of the centrifuge 20, and returned to the donor via the first line 21. (Return).
- the total amount of blood components (return blood volume) is calculated from the amount of blood collected, the amount of plasma collected, and the amount of platelet-rich plasma collected.
- the same steps as in the platelet collection operation in the first cycle are performed, except that a perfume coat return step is performed before the start of the first plasma collection step.
- the blood component sampling device 1 performs a buffy coat return (: BC return) process.
- BC return buffy coat return
- the collected buffy coat is returned to the blood storage space 146 of the mouth 142.
- the control unit 13 returns the buffy coat (step S20X in FIG. 6).
- the fourth liquid passage opening / closing means 84 and the sixth passage opening / closing means 86 are opened, and the other liquid passage opening / closing means are closed. Operate the pump 11 at a predetermined rotation speed (preferably about 60 to 250 mL / min, for example, 10 OmL / min) and rotate the centrifuge drive 10 Operates at a speed of, for example, 4800 rpm.
- a predetermined rotation speed preferably about 60 to 250 mL / min, for example, 10 OmL / min
- the buffy coat in the buffy coat collection bag 27 is transferred to the rotor 142 via the fourth tube 27a and the first line 21 through the inflow port 143 of the centrifugal separator 20 via the tube 141. It is introduced into the blood storage space 146. This and come, the air in the centrifugal separator 20 is fed into the second temporary via line 22 reservoir bag 2 6 5.
- control unit 13 determines whether there is no more buffy coat to be returned in the buffy coat collection bag 27 (step S20Y in FIG. 6). Specifically, the control unit 13 determines the number of rotations of the first liquid transfer pump 11 from the amount of buffy coat collected, and the first liquid transfer pump 11 returns the buffy coat. Judge whether it has rotated as many times as necessary.
- step S20Y If the buffy coat to be returned remains in step S20Y, that is, if the first liquid transfer pump 11 is not rotated as many times as necessary, the control unit 13 proceeds to step S20X. Return and repeat steps S20X and later. Also, in step S20Y, if there is no more buffy coat to be returned, that is, if the first liquid sending pump 11 has rotated the required number of times, the control unit 13 performs this process [20] ( (Puffy coat return step) is completed, and the procedure moves to the first plasma collection step.
- the platelet collection operation in the second cycle is the same as the platelet collection operation in the second cycle, except that the buffy coat collection step is not performed in the third cycle, and a line washing step of washing the platelet collection branch line with plasma is performed. Is performed.
- step [33] at approximately the same time as performing (second plasma collection step), the control section 13, the temporary storage bag 26 5 in temporarily collected (stored) the platelet concentrate, the leukocyte removal It is supplied to the filter 261 to filter the platelet-rich plasma, that is, to separate and remove leukocytes from the platelet-rich plasma.
- the seventh flow path opening / closing means 87 is opened.
- the concentrated platelet plasma in the temporary storage bag 26 is transferred to the platelet collection bag 26 via the tube 262a, the leukocyte removal filter 261, and the tube 263a by the head (own weight).
- the head (own weight) At this time, most of the platelet-rich plasma passes through the filter member of the leukocyte-removing filter 261.
- the leukocytes are captured by the filter member. For this reason, the leukocyte removal rate in the platelet preparation can be extremely high.
- the transfer of the concentrated platelet plasma from the temporary storage bag 26 to the platelet collection bag 26 may be performed using a pump.
- the seventh flow path opening / closing means 87 may be, for example, a clamp that can manually open and close the middle of the flow path of the tube 262a instead of the one operated under the control of the control unit 13.
- the concentrated platelet plasma collected in the temporary storage bag 26 ' is sequentially supplied to the leukocyte removal filter 261 and filtered.
- the blood component sampling device 1 performs a line cleaning step.
- the plasma is supplied from the plasma collection bag 25 to the platelet collection branch line to wash the platelet collection branch line.
- the blood component collection device 1 supplies the concentrated platelet plasma temporarily collected (stored) in the temporary storage bag 26 ′ to the leukocyte removal filter 26 1 under the control of the control unit 13.
- White blood cells in platelet plasma A filtration operation for separation and removal is performed (S401). This filtration operation is started almost simultaneously with the start of the second plasma collection step in the platelet collection operation in the final cycle. As a result, the time required for donors to be detained is reduced.
- the filtration operation is specifically performed in the following procedure. That is, under the control of the control unit 13, the seventh flow path opening / closing means 87 is opened. Thereby, the platelet concentrate in the temporary reservoir bag 2 6 5, the drop (own weight), through the tubing 262 a, leukocyte removal filter one 261 and the tube 263 a, to transfer into the platelet collection bag 26. At this time, most of the concentrated platelet plasma passes through the filtering member of the leukocyte removal filter 261, but the leukocytes are captured by the filtering member. Thus, leukocytes in the concentrated platelet plasma are separated and removed. As a result, the amount of leukocytes contaminating the platelet preparation is reduced.
- a second plasma collection step in the final cycle of platelet collection operation is started (S402).
- the seventh channel opening / closing means 87 located downstream of the temporary storage bag 26 ' is open.
- the concentrated platelet plasma collected in the second plasma collection step in the final cycle is sequentially supplied to the leukocyte removal filter 261 and filtered.
- control unit 13 calculates the supply amount of plasma (PPP) based on the following equation (S403).
- PPP supply amount (Total amount of target platelet preparation) i (PC collection amount)
- the total amount of the target platelet product is usually set before blood collection, and is determined by the specification and unit of the platelet product. Further, the PC collection amount is determined by the total number of rotations of the first liquid feed pump 11 when the fourth flow path opening / closing means 84 is opened.
- the control unit 13 supplies plasma (PPP supply) to the platelet collection branch line (S404, step S327 in FIG. 7).
- PPP supply plasma
- the control unit 13 controls plasma (PPP supply) to the platelet collection branch line (S404, step S327 in FIG. 7).
- the rotation speed and the rotation speed of the first liquid feed pump 11 are controlled by the control unit 13.
- the rotation speed of the second liquid sending pump 11 is preferably about 25 OmL min or less, more preferably about 40 to 25 OmL / min.
- the rotation speed of the mouth 142 is higher than the rotation speed of the rotor 144 in the above steps [30:] to [36] by, for example, about 300 to 800 rpm. It is preferably set to about 500 to 550 rpm.
- the plasma in the plasma collection bag 25 is transferred to the first tube 25a, the first line 21, the rotor 144 (centrifuge 20), the second line 22 and the tube.
- the temporary storage bag 26 5 that is, from the upstream side of the temporary storage bag (first container) 26, the temporary storage bag 26 5 , the tube 26 2 a, the leukocyte depletion filter 1 26 1, and the tube 2 After passing through 63 a, it is introduced (supplied) into the platelet collection bag 26.
- the platelets remaining in the leukocyte removal filter 26 1 and the flow path of the tube 26 3 a are stored in the platelet collection bag 26 together with the plasma. Since it is recovered, the yield of platelets in the platelet preparation can be increased.
- the yield of platelets in the platelet preparation can be further improved.
- the total amount of the platelet preparation (the blood component in the platelet collection bag 26) is adjusted by the supply amount of the plasma. Thereby, the operation of separately adjusting the total amount of the platelet preparation can be omitted.
- since such adjustment can be performed in the blood component collection circuit 2 (closed state), there is an advantage that an aseptic state can be maintained.
- the supply amount of such plasma is preferably about 5 to 20 OmL, and more preferably about 12 to 15 OmL.
- the supplied amount of plasma is detected by the weight sensor 16 as a change (decrease) in the weight of the plasma collection bag 25.
- the control unit 13 may control the first liquid sending pump 11 to temporarily stop while maintaining the rotation of the mouth 142 once.
- the buffy coat layer 132 and the erythrocyte layer 133 that had diffused (increased in thickness) in the blood storage space 146 of the mouth 142 were compressed.
- this step [3A] line washing step
- this step [3A] after the discharge of platelet concentrate from the temporary storage bag 26 within 5 has been completed, may be started.
- This can be realized by, for example, installing a bubble sensor or the like capable of detecting the presence of bubbles in the flow path in the tube 262a near the temporary storage bag 26 '.
- the operation of collecting platelets is not limited to three times, and may be performed once or twice, or four or more times as necessary.
- leukocytes are separated and removed by the leukocyte removal filter 261 from the concentrated platelet plasma separated and collected from blood, so that a platelet preparation with extremely low leukocyte contamination can be obtained.
- the platelets remaining in the leukocyte removal filter 261 and the flow path of the tube 263a are washed away with the plasma and collected in the platelet collection bag 26. Therefore, a platelet preparation having an extremely high platelet yield can be obtained.
- platelets are collected (washed out) using plasma (blood components), a higher quality platelet preparation can be obtained as compared with, for example, a case using physiological saline or an anticoagulant.
- the configuration of the blood component collection circuit 2 can also be set as appropriate, and is not limited to the illustrated configuration.
- a tube (line) for connecting the plasma collection bag 25 and the platelet collection branch line may be provided.
- the method of supplying (transferring) the plasma in the plasma collection bag 25 to the platelet collection branch line may be either a method using a head or a method using a pump.
- the plasma collection bag 25 is connected to the upstream side of the temporary storage bag 26.
- a second plasma collection bag different from the plasma collection bag 25 is provided, and the plasma to be supplied to the platelet collection branch line is stored in the second plasma collection bag in the line washing step. You can also.
- the conditions in each step of the platelet collection operation can be set as appropriate, and any steps may be added and / or omitted as necessary. Can also.
- the blood component collection device of the present invention has been described based on the illustrated embodiments, but the present invention is not limited to these embodiments.
- Each component of the blood component collection device can be replaced with any component having the same function.
- the optical sensor is not limited to the illustrated one, and may be, for example, a line sensor or the like.
- the blood component collection device of the present invention is not limited to the case where it is applied to obtain a platelet product, and may be applied, for example, to a case where a plasma product, an albumin product, an erythrocyte product, etc. are produced from blood.
- the cells separated and removed by the cell separation filter are not limited to leukocytes.
- the conditions for each step in the platelet collection operation are shown below.
- the interface of the blood component to be detected was the interface between the plasma layer and the puffy coat layer.
- Mouth and evening speed 4800 rpm
- Mouth and evening speed 4800 rpm
- the blood component collection circuit (“Termore Feresis System Set (with a leukocyte removal filter)” manufactured by Terumo Corporation) and the blood component collection device ("Termore Feresis System AC-550" manufactured by Terumo Corporation) Blood shown in Fig. 1
- the component sampling device was assembled. A platelet collection operation (four times) was performed using this apparatus in the same manner as in the above example except that the line washing step was omitted.
- the platelet collection operation of the comparative example was performed two weeks after the platelet collection operation of the example was performed using the same donor as in the example.
- the amount of the concentrated platelet plasma in the temporary storage bags and the amount of the platelet preparation in the platelet collection nozzle obtained in the examples and comparative examples was measured.
- the platelet-rich plasma in the temporary storage bag and the platelet preparation in the platelet collection bag were sampled, and the platelet count and white blood cell count contained therein were measured.
- a hemocytometer Sysmex®, Sysmex® SE-9000
- the lower limit of leukocyte count in Sy smex (R) SE-9000 is O. lxl Therefore, the number of leukocytes was measured by the Nage otte [1: 9] method for the samples below the lower limit of measurement.
- the loss of platelets in the platelet collection branch line can be further reduced by performing the line washing step, as compared with the comparative example.
- the yield of platelets in the formulation could be higher.
- the yield of platelets in the example was 96.35%
- the yield of platelets in the comparative example was 92.37%
- the yield of platelets in the platelet preparation could be improved by about 4%.
- the yield is represented by (platelet count in platelet collection bag / platelet count in temporary storage bag) XI 00 (%).
- the blood component collection apparatus of the present invention in order to separate and remove predetermined cells by the cell separation filter, when obtaining a blood product such as a platelet product, the removal rate of leukocytes (especially lymphocytes) in (blood products) is increased, and the probability of fever, alloantigen sensitization, virus infection, etc. can be reduced, and safety is high.
- a blood product such as a platelet product
- the blood component collecting apparatus of the present invention when obtaining a blood product such as a platelet product, the platelet remaining in the cell separation filter is collected through, for example, plasma (blood component).
- plasma blood component
- the platelet yield in platelet preparations is increased, and platelets are collected using blood components, so that a high-quality platelet preparation (blood preparation) can be obtained.
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/473,168 US7186231B2 (en) | 2001-03-28 | 2002-03-19 | Blood component collection method |
EP02705362.8A EP1374927B1 (en) | 2001-03-28 | 2002-03-19 | Method of collecting a blood component |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001094102A JP4050477B2 (ja) | 2001-03-28 | 2001-03-28 | 血液成分採取装置 |
JP2001-94102 | 2001-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002078769A1 true WO2002078769A1 (fr) | 2002-10-10 |
Family
ID=18948351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002625 WO2002078769A1 (fr) | 2001-03-28 | 2002-03-19 | Dispositif de collecte de composants sanguins |
Country Status (4)
Country | Link |
---|---|
US (1) | US7186231B2 (ja) |
EP (1) | EP1374927B1 (ja) |
JP (1) | JP4050477B2 (ja) |
WO (1) | WO2002078769A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097231A1 (fr) * | 2004-04-06 | 2005-10-20 | Shanghai Jiangxia Blood Technology Co., Ltd. | Appareil de filtration extracorporel destine a eliminer les lipides du plasma |
CN104491945A (zh) * | 2014-12-31 | 2015-04-08 | 成都市佳颖医用制品有限公司 | 一种血浆采集装置 |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601268B2 (en) * | 2003-05-27 | 2009-10-13 | Haemonetics Corporation | Continuous blood filtration and method of use |
JP4871496B2 (ja) * | 2004-06-16 | 2012-02-08 | テルモ株式会社 | 血液成分採取装置 |
JP4594029B2 (ja) * | 2004-10-13 | 2010-12-08 | テルモ株式会社 | 血液成分採取装置 |
JP4758663B2 (ja) * | 2005-03-09 | 2011-08-31 | テルモ株式会社 | 血液成分採取装置 |
US20060226087A1 (en) * | 2005-04-08 | 2006-10-12 | Mission Medical, Inc. | Method and apparatus for blood separations |
US20060226086A1 (en) * | 2005-04-08 | 2006-10-12 | Robinson Thomas C | Centrifuge for blood processing systems |
US7403125B2 (en) * | 2005-05-06 | 2008-07-22 | Accuri Cytometers, Inc. | Flow cytometry system with bubble detection |
JP4848143B2 (ja) * | 2005-06-17 | 2011-12-28 | テルモ株式会社 | 血液成分採取装置 |
US7996188B2 (en) | 2005-08-22 | 2011-08-09 | Accuri Cytometers, Inc. | User interface for a flow cytometer system |
US7776268B2 (en) * | 2005-10-13 | 2010-08-17 | Accuri Cytometers, Inc. | User interface for a fluidic system of a flow cytometer |
US8303894B2 (en) | 2005-10-13 | 2012-11-06 | Accuri Cytometers, Inc. | Detection and fluidic system of a flow cytometer |
US8017402B2 (en) * | 2006-03-08 | 2011-09-13 | Accuri Cytometers, Inc. | Fluidic system for a flow cytometer |
US7857005B2 (en) * | 2005-12-07 | 2010-12-28 | Accuri Cytometers, Inc. | Pulsation attenuator for a fluidic system |
US8283177B2 (en) | 2006-03-08 | 2012-10-09 | Accuri Cytometers, Inc. | Fluidic system with washing capabilities for a flow cytometer |
US7780916B2 (en) * | 2006-03-08 | 2010-08-24 | Accuri Cytometers, Inc. | Flow cytometer system with unclogging feature |
US7981661B2 (en) * | 2006-04-17 | 2011-07-19 | Accuri Cytometers, Inc. | Flow cytometer system with sheath and waste fluid measurement |
US8715573B2 (en) * | 2006-10-13 | 2014-05-06 | Accuri Cytometers, Inc. | Fluidic system for a flow cytometer with temporal processing |
US8445286B2 (en) | 2006-11-07 | 2013-05-21 | Accuri Cytometers, Inc. | Flow cell for a flow cytometer system |
US7739060B2 (en) * | 2006-12-22 | 2010-06-15 | Accuri Cytometers, Inc. | Detection system and user interface for a flow cytometer system |
US8432541B2 (en) | 2007-12-17 | 2013-04-30 | Accuri Cytometers, Inc. | Optical system for a flow cytometer with an interrogation zone |
JP4528863B2 (ja) * | 2008-02-29 | 2010-08-25 | ヘモネティクス・コーポレーション | アフェレーシス装置 |
US8454548B2 (en) * | 2008-04-14 | 2013-06-04 | Haemonetics Corporation | System and method for plasma reduced platelet collection |
US8628489B2 (en) * | 2008-04-14 | 2014-01-14 | Haemonetics Corporation | Three-line apheresis system and method |
JP2009101187A (ja) * | 2009-01-14 | 2009-05-14 | Terumo Corp | 血液成分採取回路 |
US8834402B2 (en) | 2009-03-12 | 2014-09-16 | Haemonetics Corporation | System and method for the re-anticoagulation of platelet rich plasma |
US8507279B2 (en) | 2009-06-02 | 2013-08-13 | Accuri Cytometers, Inc. | System and method of verification of a prepared sample for a flow cytometer |
US20110061471A1 (en) * | 2009-06-02 | 2011-03-17 | Rich Collin A | System and method of verification of a sample for a flow cytometer |
EP2264150A1 (en) * | 2009-06-09 | 2010-12-22 | Astley E. Smith | Triple spin, double pool and revolumization process for concentrating platelets and derivative platelets concentrate |
EP2515966B1 (en) * | 2009-12-22 | 2017-03-29 | Terumo BCT, Inc. | Methods and apparatus for collection of filtered blood components, in particular red blood cells |
WO2011106402A1 (en) | 2010-02-23 | 2011-09-01 | Accuri Cytometers, Inc. | Method and system for detecting fluorochromes in a flow cytometer |
US9551600B2 (en) | 2010-06-14 | 2017-01-24 | Accuri Cytometers, Inc. | System and method for creating a flow cytometer network |
EP2633284B1 (en) | 2010-10-25 | 2021-08-25 | Accuri Cytometers, Inc. | Systems and user interface for collecting a data set in a flow cytometer |
JP5490966B2 (ja) | 2010-11-05 | 2014-05-14 | ヘモネティクス・コーポレーション | 自動化された血小板洗浄のためのシステムおよび方法 |
US8512942B2 (en) * | 2010-11-29 | 2013-08-20 | New York Blood Center, Inc. | Method of blood pooling and storage |
US9302042B2 (en) | 2010-12-30 | 2016-04-05 | Haemonetics Corporation | System and method for collecting platelets and anticipating plasma return |
US11386993B2 (en) | 2011-05-18 | 2022-07-12 | Fenwal, Inc. | Plasma collection with remote programming |
US10167310B2 (en) | 2012-01-31 | 2019-01-01 | Estar Technologies Ltd | System and method for producing interleukin receptor antagonist (IRA) |
WO2014102888A1 (ja) * | 2012-12-24 | 2014-07-03 | テルモ株式会社 | 血液成分分離装置 |
EP2962709B1 (en) * | 2013-02-26 | 2017-12-06 | Terumo Kabushiki Kaisha | Blood component separation apparatus |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
CN104667362A (zh) * | 2015-03-24 | 2015-06-03 | 傅敏 | 全自动全血采集分离机及配套的一次性使用采集分离装置 |
CN112842233A (zh) | 2015-04-03 | 2021-05-28 | 席勒斯科技有限公司 | 外科流体管理系统 |
RU2623078C1 (ru) * | 2016-03-09 | 2017-06-21 | Общество с ограниченной ответственностью "Научно-производственное предприятие "Технологические инновации" | Автономная передвижная стойка для лейкофильтрации компонентов крови |
WO2018046268A1 (en) * | 2016-09-06 | 2018-03-15 | Fresenius Kabi Deutschland Gmbh | Automated method for leukocyte collection from whole blood |
EP3512577A1 (en) | 2016-09-16 | 2019-07-24 | Fenwal, Inc. | Blood separation systems and methods employing centrifugal and spinning membrane separation techniques |
US10758652B2 (en) | 2017-05-30 | 2020-09-01 | Haemonetics Corporation | System and method for collecting plasma |
US10792416B2 (en) | 2017-05-30 | 2020-10-06 | Haemonetics Corporation | System and method for collecting plasma |
US11412967B2 (en) | 2018-05-21 | 2022-08-16 | Fenwal, Inc. | Systems and methods for plasma collection |
JP6976458B2 (ja) | 2018-05-21 | 2021-12-08 | フェンウォール、インコーポレイテッド | 血漿収集量を最適化するためのシステムおよび方法 |
EP3705146A3 (en) | 2019-03-05 | 2020-11-25 | Fenwal, Inc. | Collection of mononuclear cells and peripheral blood stem cells |
US11890399B2 (en) | 2019-05-23 | 2024-02-06 | Fenwal, Inc. | Centrifugal separation and collection of red blood cells, plasma, or both red blood cells and plasma |
EP4238595A3 (en) | 2019-05-23 | 2023-11-29 | Fenwal, Inc. | Adjustment of target interface location between separated fluid components in a centrifuge |
US11957998B2 (en) * | 2019-06-06 | 2024-04-16 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
US11957828B2 (en) | 2019-09-16 | 2024-04-16 | Fenwal, Inc. | Dynamic adjustment of algorithms for separation and collection of blood components |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265407A (ja) * | 1994-03-29 | 1995-10-17 | Terumo Corp | 細胞分離器具および細胞分離方法 |
WO1997005938A1 (en) | 1995-08-09 | 1997-02-20 | Baxter International Inc. | Systems and methods for separating erythrocytes |
WO2001024284A1 (en) | 1999-09-27 | 2001-04-05 | Lumileds Lighting, U.S., Llc | A light emitting diode device that produces white light by performing complete phosphor conversion |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2696551B1 (fr) * | 1992-07-13 | 1995-06-23 | Pall Corp | Systeme automatique et procede pour le traitement d'un fluide biologique. |
US5637082A (en) * | 1996-02-22 | 1997-06-10 | Haemonetics Corporation | Adaptive apheresis apparatus |
US5865785A (en) * | 1996-02-23 | 1999-02-02 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US6752777B1 (en) * | 1997-06-16 | 2004-06-22 | Terumo Kabushiki Kaisha | Blood component collecting apparatus |
US6945411B1 (en) * | 1999-03-16 | 2005-09-20 | Pall Corporation | Biological fluid filter and system |
US7686779B1 (en) * | 1999-10-01 | 2010-03-30 | Caridian BCT, Inc | Extracorporeal blood processing methods and apparatus |
-
2001
- 2001-03-28 JP JP2001094102A patent/JP4050477B2/ja not_active Expired - Lifetime
-
2002
- 2002-03-19 US US10/473,168 patent/US7186231B2/en not_active Expired - Lifetime
- 2002-03-19 EP EP02705362.8A patent/EP1374927B1/en not_active Expired - Lifetime
- 2002-03-19 WO PCT/JP2002/002625 patent/WO2002078769A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265407A (ja) * | 1994-03-29 | 1995-10-17 | Terumo Corp | 細胞分離器具および細胞分離方法 |
WO1997005938A1 (en) | 1995-08-09 | 1997-02-20 | Baxter International Inc. | Systems and methods for separating erythrocytes |
WO2001024284A1 (en) | 1999-09-27 | 2001-04-05 | Lumileds Lighting, U.S., Llc | A light emitting diode device that produces white light by performing complete phosphor conversion |
Non-Patent Citations (1)
Title |
---|
See also references of EP1374927A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097231A1 (fr) * | 2004-04-06 | 2005-10-20 | Shanghai Jiangxia Blood Technology Co., Ltd. | Appareil de filtration extracorporel destine a eliminer les lipides du plasma |
CN104491945A (zh) * | 2014-12-31 | 2015-04-08 | 成都市佳颖医用制品有限公司 | 一种血浆采集装置 |
Also Published As
Publication number | Publication date |
---|---|
JP4050477B2 (ja) | 2008-02-20 |
EP1374927A1 (en) | 2004-01-02 |
US7186231B2 (en) | 2007-03-06 |
US20040112808A1 (en) | 2004-06-17 |
EP1374927A4 (en) | 2010-05-19 |
JP2002291872A (ja) | 2002-10-08 |
EP1374927B1 (en) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002078769A1 (fr) | Dispositif de collecte de composants sanguins | |
US8449488B2 (en) | Blood component collection apparatus and method | |
JP4299452B2 (ja) | 血小板採取装置 | |
JP3817079B2 (ja) | 血液成分採取装置 | |
JP3944279B2 (ja) | 血液成分採取装置 | |
JP3715338B2 (ja) | 血液成分分離装置 | |
JP3850429B2 (ja) | 血液成分分離装置 | |
JP3848798B2 (ja) | 血液成分採取装置 | |
JP2005110748A (ja) | 血液成分採取装置 | |
JP4558401B2 (ja) | 血液成分採取装置 | |
JP4255166B2 (ja) | 血液成分採取装置 | |
JP4344592B2 (ja) | 血液成分採取装置 | |
JP4771452B2 (ja) | 血液成分採取装置 | |
JP3936142B2 (ja) | 血液成分採取装置 | |
JP4956528B2 (ja) | 血液成分採取装置 | |
JP4500618B2 (ja) | 血液成分採取装置 | |
JP4060504B2 (ja) | 血液成分採取装置 | |
JP4727058B2 (ja) | 血液成分採取装置 | |
JP4948712B2 (ja) | 血液成分採取装置 | |
JP4607508B2 (ja) | 血液成分採取装置 | |
JP4871496B2 (ja) | 血液成分採取装置 | |
JP2005177191A (ja) | 採血装置 | |
JP2002272837A (ja) | 血液成分採取装置 | |
JP2002272836A (ja) | 血液成分採取装置 | |
JP2005218716A (ja) | 血液成分採取装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002705362 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473168 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002705362 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |